Greetings Everyone Stoney / Van / Ted - you think within next 2-3 years we will have phone calls with realistic three-dimensional holographic moving images like the one we saw in Star Wars film. Where to go with Apple Stock Advertising Never Lies - I thought I drop this here.
$8.10 high “ Mind Medicine Inc.'s stock jumped 24% early Thursday, after the biotech company said the Food and Drug Administration has granted breakthrough designation for its MM120 LSD-based treatment for generalized anxiety disorder. The FDA move will expedite the development of the therapy, which has already shown positive results in a Phase 2 trial, showing statistically significant improvement in scores by week four compared with placebo. The company said its Phase 2b trial met its key secondary endpoint and that 12-week data showed clinically and statistically significant durability of activity. "That MM120 exhibited rapid and robust efficacy, solidly sustained for 12 weeks after a single dose, is truly remarkable, " said Dr. David Feifel, Ph.D., and professor emeritus of psychiatry at the University of California, San Diego, and director of the Kadima Neuropsychiatry Institute in La Jolla, California. Feifel was an investigator in the MM120 study. $Mind Medicine (MNMD.US)$ is now planning to hold end-of-Phase 2 meetings with the FDA in the first half of the year, and aims to initiate a Phase 3 trial in the second half. The Phase 2b trial was based on a 100 ug dose and showed a 65% clinical response rate and a 48% clinical remission rate that held through week 12 compared with placebo. GAD presents a significant unmet medical need for the many patients who do not respond to existing medications. Separately, MindMed announced it has priced an offering 16.6 million common shares at $6 a share, which compares with its closing price Wednesday at $5.94. The company has entered into a concurrent private placement of 12.5 million shares at the same price. Proceeds of the deal are expected to come to about $75 million. The private placement will bring in new investors Deep Track Capital and Commodore Capital, while the underwritten offering will bring in new investors Ally Bridge Group, Driehaus Capital Management, Great Point Partners, LLC, Janus Henderson Investors, Marshall Wace, Octagon Capital, Soleus Capital, Special Situations Funds, Woodline Partners LP and a leading biotechnology investor associated with one of the largest alternative-asset managers. Other companies seeking to develop therapies using psychedelics were also higher Thursday. Atai Life Sciences N.V. (ATA) was up 5% and Compass Pathways PLC (CMPS) was up 10%. ` MindMed's stock has gained 78% in the last 12 months, while the S&P 500 SPX has gained 28%. From the archive: 20-year-old investor who made $110 million on a meme stock is now pushing for change at psychedelics company MindMed -Ciara Linnane
Stoney, you usually give notice that you’re taking a break. I am worried about you! Did you try eagle lifting before your hernia healed? No showing off to the yoga goddesses.
You know Stoney never shows up after a big loser. In this case he has 4. GTLB, BE, VSCO, WKSP. We won't see Stoney for a week.